Colon Cancer - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 426

Colon Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Colon Cancer - Pipeline Review, H2 2012', provides an overview of the Colon Cancer therapeutic pipeline. This report provides information on the therapeutic development for Colon Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Cancer. 'Colon Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Colon Cancer.
- A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Colon Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Colon Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Colon Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Colon Cancer Therapeutic Products under Development, Key Players in Colon Cancer Therapeutics, Colon Cancer Pipeline Overview, Colon Cancer Pipeline, Colon Cancer Pipeline Assessment

2
List of Tables 9
List of Figures 11
Introduction 12
REPORT COVERAGE 12
Colon Cancer Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Colon Cancer 14
Colon Cancer Therapeutics under Development by Companies 16
Colon Cancer Therapeutics under Investigation by Universities/Institutes 23
Late Stage Products 28
Comparative Analysis 28
Mid Clinical Stage Products 29
Comparative Analysis 29
Early Clinical Stage Products 30
Comparative Analysis 30
Discovery and Pre-Clinical Stage Products 31
Comparative Analysis 31
Colon Cancer Therapeutics – Products under Development by Companies 32
Colon Cancer Therapeutics – Products under Investigation by Universities/Institutes 39
Companies Involved in Colon Cancer Therapeutics Development 45
F. Hoffmann-La Roche Ltd. 45
AstraZeneca PLC 46
Bioniche Life Sciences, Inc. 47
Bio-Path Holdings, Inc. 48
ZIOPHARM Oncology, Inc. 49
ImClone Systems Incorporated 50
Santaris Pharma A/S 51
Alfacell Corporation 52
Merck KGaA 53
Alchemia Limited 54
Enzo Biochem, Inc. 55
AEterna Zentaris Inc. 56
ImmunoCellular Therapeutics, Ltd. 57
Idera Pharmaceuticals, Inc. 58
Lorus Therapeutics Inc 59
Bio-Bridge Science, Inc. 60
Bionomics Limited 61
Cleveland BioLabs, Inc. 62
Compugen Ltd. 63
Paladin Labs Inc. 64
Critical Outcome Technologies Inc. 65
Curis, Inc. 66
Telik, Inc. 67
Zenotech Laboratories Limited 68
Dendreon Corporation 69
Choongwae Pharma Corp 70
Green Cross Corporation 71
Innocell Corporation 72
Synta Pharmaceuticals Corp. 73
CrystalGenomics, Inc. 74
Sareum Holdings plc 75
Transgene Biotek Ltd 76
ISA Pharmaceuticals B.V. 105
ImQuest Life Sciences 106
TAU Therapeutics, LLC 107
CytomX, LLC. 108
Colon Cancer – Therapeutics Assessment 109
Assessment by Monotherapy Products 109
Assessment by Combination Products 110
Assessment by Route of Administration 111
Assessment by Molecule Type 114
Drug Profiles 117
IMO-2055 - Drug Profile 117
Erbitux - Drug Profile 119
HyFIVE - Drug Profile 120
LOR-1284 - Drug Profile 121
IL-17E - Drug Profile 122
CU-903 - Drug Profile 123
AEZS-126 - Drug Profile 124
Immunalon - Drug Profile 125
ICT-037 - Drug Profile 126
ICT-109 - Drug Profile 127
ATI-1150 - Drug Profile 129
Chk1 Program - Drug Profile 130
Aurora Kinase Program - Drug Profile 131
CA-9 - Drug Profile 132
Carcinoembryonic Antigen - Drug Profile 133
COTI-2 - Drug Profile 134
XMT-1001 - Drug Profile 135
Ganetespib - Drug Profile 136
CGEN-25008 - Drug Profile 138
Mycobacterial Cell Wall-DNA Complex Program - Drug Profile 139
CBLC137 - Drug Profile 140
Curaxin CBLC102 - Drug Profile 141
Protectan CBLB502 - Drug Profile 144
TLK60404 - Drug Profile 146
TLK60596 - Drug Profile 147
AB-16B5 - Drug Profile 148
DDS-06E - Drug Profile 149
AL3810 - Drug Profile 150
AL3818 - Drug Profile 151
CG200745 - Drug Profile 152
VLN244 - Drug Profile 153
OncoVAX - Drug Profile 154
Rosuvastatin - Drug Profile 156
Xelox - Drug Profile 157
Kevetrin - Drug Profile 158
BP-100-2.01 - Drug Profile 161
BP-100-1.02 - Drug Profile 162
BNC105 - Drug Profile 163
ATN-658 - Drug Profile 164
PI3K/MEK Inhibitor - Drug Profile 165
OMP-21M18 - Drug Profile 166
DMS612 - Drug Profile 168
RX-0183 - Drug Profile 169
Leucovorin Calcium + Tegafur-Uracil - Drug Profile 199
S-1 - Drug Profile 200
Fluorouracil + Leucovorin Calcium - Drug Profile 201
BP-100-1.01 - Drug Profile 202
FOLFIRI - Drug Profile 203
Sunitinib + Capecitabine - Drug Profile 205
Fluorouracil + Levamisole Hydrochloride - Drug Profile 208
Fluorouracil + Leucovorin + Levamisole - Drug Profile 209
Oxaliplatin + Capecitabine + Panitumumab - Drug Profile 211
FOLFOX-4 - Drug Profile 213
Erbitux + FOLFOX - Drug Profile 214
Bevacizumab + XELOX - Drug Profile 216
Fluorouracil + Irinotecan + Leucovorin - Drug Profile 218
Cetuximab + Fluorouracil + Irinotecan + Leucovorin - Drug Profile 220
PHA-793887 - Drug Profile 222
mFOLFOX6 + Bevacizumab - Drug Profile 223
Folic Acid - Drug Profile 225
Fluorouracil + Semustine + Vincristine - Drug Profile 226
Xeliri + Avastin - Drug Profile 228
SIR-spheres + Cetuximab + Irinotecan - Drug Profile 230
Oxaliplatin + Folinic Acid + 5-Fluorouracil - Drug Profile 232
Rebastinib - Drug Profile 234
Capecitabine + CPT-11 - Drug Profile 236
UFT + Leucovorin Calcium - Drug Profile 238
Cisplatin - Drug Profile 240
IPP-204106 - Drug Profile 241
Fluorouracil + Leucovorin Calcium - Drug Profile 242
OxCap + Panitumumab - Drug Profile 244
TS-1 + Cisplatin + Everolimus - Drug Profile 246
AVX701 - Drug Profile 248
TTT-3002 - Drug Profile 249
IQP-0304 - Drug Profile 250
Immuncell-LC - Drug Profile 251
OxMdG + Panitumumab - Drug Profile 253
OPTIMOX Therapy - Drug Profile 255
5-Fluorouracil + Folinic Acid + CPT-11 - Drug Profile 257
UFT + LV - Drug Profile 259
TS-1 + UFT - Drug Profile 260
Cancer Vaccine + Basiliximab - Drug Profile 261
FOLFIRI - Drug Profile 262
5-Fluorouracil + Leucovorin + Cisplatin - Drug Profile 296
Xerecept + Avastin - Drug Profile 297
Drugs For Cancer - Drug Profile 299
Oxaliplatin + Leucovorin + Fluorouracil - Drug Profile 300
X-480 - Drug Profile 302
PT 128 - Drug Profile 303
Probodies Program - Drug Profile 304
VB6-011 - Drug Profile 305
VB6-050 - Drug Profile 306
Gemcitabine + Fluorouracil + Folinic Acid + Oxaliplatin + GM-CSF + Aldesleukine - Drug Profile 307
DPK-M2 - Drug Profile 309
EC-7072 - Drug Profile 310
DPK-M1 - Drug Profile 311
CPT-11 + TS-1 + Cetuximab - Drug Profile 312
TTL 1177 - Drug Profile 313
EZN-3892 - Drug Profile 314
Oxaliplatin + Fluorouracil + Levofolinate - Drug Profile 315
NLG8189 + Ad-p53 - Drug Profile 316
FOLFOX 4 - Drug Profile 318
Chk1 Inhibitor + Gemcitabine - Drug Profile 319
Aurora Kinases + FLT3 Kinase Program - Drug Profile 320
OXT-922 - Drug Profile 322
Betulinic Acid - Drug Profile 323
P53-SLP - Drug Profile 324
rhErbB3-f - Drug Profile 326
PNT200 - Drug Profile 327
PNT300 - Drug Profile 328
PNT400 - Drug Profile 329
PNT500 - Drug Profile 330
PNT600 - Drug Profile 331
ONS-1015 - Drug Profile 354
ONS-1035 - Drug Profile 356
Vaccine For Metastatic Colon Cancer - Drug Profile 358
CFAK-Y15 - Drug Profile 359
MG1102 - Drug Profile 360
A33-Ac-225 - Drug Profile 361
CNDO-109 - Drug Profile 362
Hyaluronic Acid-Camptosar + Erbitux + Avastin - Drug Profile 364
Naproxen - Drug Profile 365
Zycan - Drug Profile 366
NO-Naproxen - Drug Profile 367
TBL-0306C - Drug Profile 368
CG0070IT - Drug Profile 369
CWF-0701 - Drug Profile 370
KaroMab-GEX - Drug Profile 371
EC-8042 - Drug Profile 372
NOV110401 - Drug Profile 373
Colon Cancer Therapeutics – Drug Profile Updates 374
Colon Cancer Therapeutics – Discontinued Products 401
Colon Cancer Therapeutics - Dormant Products 402
Colon Cancer – Product Development Milestones 406
Featured News & Press Releases 406
Appendix 412
Methodology 412
Coverage 412
Secondary Research 412
Primary Research 412
Expert Panel Validation 412
Contact Us 413
Disclaimer 413

List of Tables
Number of Products Under Development for Colon Cancer, H2 2012 27
Products under Development for Colon Cancer – Comparative Analysis, H2 2012 28
Number of Products under Development by Companies, H2 2012 30
Number of Products under Development by Companies, H2 2012 (Contd..1) 31
Number of Products under Development by Companies, H2 2012 (Contd..2) 32
Number of Products under Development by Companies, H2 2012 (Contd..3) 33
Number of Products under Development by Companies, H2 2012 (Contd..4) 34
Number of Products under Development by Companies, H2 2012 (Contd..5) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 38
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 39
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 40
Comparative Analysis by Late Stage Development, H2 2012 41
Comparative Analysis by Mid Clinical Stage Development, H2 2012 42
Comparative Analysis by Early Clinical Stage Development, H2 2012 43
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 44
Products under Development by Companies, H2 2012 45
Products under Development by Companies, H2 2012 (Contd..1) 46
Products under Development by Companies, H2 2012 (Contd..2) 47
Products under Development by Companies, H2 2012 (Contd..3) 48
Products under Development by Companies, H2 2012 (Contd..4) 49
Products under Development by Companies, H2 2012 (Contd..5) 50
Products under Development by Companies, H2 2012 (Contd..6) 51
Products under Investigation by Universities/Institutes, H2 2012 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 57
F. Hoffmann-La Roche Ltd., H2 2012 58
AstraZeneca PLC, H2 2012 59
Bioniche Life Sciences, Inc., H2 2012 60
Bio-Path Holdings, Inc., H2 2012 61
ZIOPHARM Oncology, Inc., H2 2012 62
ImClone Systems Incorporated, H2 2012 63
Santaris Pharma A/S, H2 2012 64
Alfacell Corporation, H2 2012 65
Merck KGaA, H2 2012 66
Alchemia Limited, H2 2012 67
Enzo Biochem, Inc., H2 2012 68
AEterna Zentaris Inc., H2 2012 69
ImmunoCellular Therapeutics, Ltd., H2 2012 70
Idera Pharmaceuticals, Inc., H2 2012 71
Lorus Therapeutics Inc, H2 2012 72
Bio-Bridge Science, Inc., H2 2012 73
Bionomics Limited, H2 2012 74
Cleveland BioLabs, Inc., H2 2012 75
Compugen Ltd., H2 2012 76
Paladin Labs Inc., H2 2012 77
Critical Outcome Technologies Inc., H2 2012 78
Curis, Inc., H2 2012 79
Telik, Inc., H2 2012 80
Zenotech Laboratories Limited, H2 2012 81
Dendreon Corporation, H2 2012 82
Choongwae Pharma Corp, H2 2012 83
Green Cross Corporation, H2 2012 84
Innocell Corporation, H2 2012 85
Synta Pharmaceuticals Corp., H2 2012 86
CrystalGenomics, Inc., H2 2012 87
Sareum Holdings plc, H2 2012 88
Transgene Biotek Ltd, H2 2012 89
Rexahn Pharmaceuticals, Inc., H2 2012 90
MabVax Therapeutics, Inc., H2 2012 91
Immupharma Plc, H2 2012 92
Actinium Pharmaceuticals, Inc., H2 2012 93
Glycotope GmbH, H2 2012 94
Provecs Medical GmbH, H2 2012 95
Alethia Biotherapeutics Inc., H2 2012 96
Coronado Biosciences, Inc., H2 2012 97
OncoMed Pharmaceuticals, Inc., H2 2012 98
AlphaVax, Inc., H2 2012 99
Azaya Therapeutics, Inc., H2 2012 100
Deciphera Pharmaceuticals, LLC, H2 2012 101
ProNAi Therapeutics, Inc., H2 2012 102
Mersana Therapeutics, Inc., H2 2012 103
Affichem, H2 2012 104
Advenchen Laboratories, LLC, H2 2012 105
NovaLead Pharma Pvt. Ltd., H2 2012 106
Vaccinogen, Inc., H2 2012 107
Etubics Corporation, H2 2012 108
NewLink Genetics Corporation, H2 2012 109
Tautatis Incorporated, H2 2012 110
Viventia Biotechnologies Inc., H2 2012 111
Merus B.V., H2 2012 112
Pique Therapeutics, H2 2012 113
Cellceutix Pharmaceuticals, Inc., H2 2012 114
Celtic Pharmaceutical Holdings L.P., H2 2012 115
EyeGene, Inc., H2 2012 116
DEKK-TEC, Inc., H2 2012 117
ISA Pharmaceuticals B.V., H2 2012 118
ImQuest Life Sciences, H2 2012 119
TAU Therapeutics, LLC, H2 2012 120
CytomX, LLC., H2 2012 121
Assessment by Monotherapy Products, H2 2012 122
Assessment by Combination Products, H2 2012 123
Assessment by Stage and Route of Administration, H2 2012 126
Assessment by Stage and Molecule Type, H2 2012 129
Colon Cancer Therapeutics – Drug Profile Updates 387
Colon Cancer Therapeutics – Discontinued Products 414
Colon Cancer Therapeutics – Dormant Products 415

List of Figures
Number of Products under Development for Colon Cancer, H2 2012 27
Products under Development for Colon Cancer – Comparative Analysis, H2 2012 28
Products under Development by Companies, H2 2012 29
Products under Investigation by Universities/Institutes, H2 2012 36
Late Stage Products, H2 2012 41
Mid Clinical Stage Products, H2 2012 42
Early Clinical Stage Products, H2 2012 43
Discovery and Pre-Clinical Stage Products, H2 2012 44
Assessment by Monotherapy Products, H2 2012 122
Assessment by Combination Products, H2 2012 123
Assessment by Route of Administration, H2 2012 124
Assessment by Stage and Route of Administration, H2 2012 125
Assessment by Molecule Type, H2 2012 127
Assessment by Stage and Molecule Type, H2 2012 128

- F. Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- Bioniche Life Sciences, Inc.
- Bio-Path Holdings, Inc.
- ZIOPHARM Oncology, Inc.
- ImClone Systems Incorporated
- Santaris Pharma A/S
- Alfacell Corporation
- Merck KGaA
- Alchemia Limited
- Enzo Biochem, Inc.
- AEterna Zentaris Inc.
- ImmunoCellular Therapeutics, Ltd.
- Idera Pharmaceuticals, Inc.
- Lorus Therapeutics Inc
- Bio-Bridge Science, Inc.
- Bionomics Limited
- Cleveland BioLabs, Inc.
- Compugen Ltd.
- Paladin Labs Inc.
- Critical Outcome Technologies Inc.
- Curis, Inc.
- Telik, Inc.
- Zenotech Laboratories Limited
- Dendreon Corporation
- Choongwae Pharma Corp
- Green Cross Corporation
- Innocell Corporation
- Synta Pharmaceuticals Corp.
- CrystalGenomics, Inc.
- Sareum Holdings plc
- Transgene Biotek Ltd
- Rexahn Pharmaceuticals, Inc.
- MabVax Therapeutics, Inc.
- Immupharma Plc
- Actinium Pharmaceuticals, Inc.
- Glycotope GmbH
- Provecs Medical GmbH
- Alethia Biotherapeutics Inc.
- Coronado Biosciences, Inc.
- OncoMed Pharmaceuticals, Inc.
- AlphaVax, Inc.
- Azaya Therapeutics, Inc.
- Deciphera Pharmaceuticals, LLC
- ProNAi Therapeutics, Inc.
- Mersana Therapeutics, Inc.
- Affichem
- Advenchen Laboratories, LLC
- NovaLead Pharma Pvt. Ltd.
- Vaccinogen, Inc.
- Etubics Corporation
- NewLink Genetics Corporation
- Tautatis Incorporated
- Viventia Biotechnologies Inc.
- Merus B.V.
- Pique Therapeutics
- Cellceutix Pharmaceuticals, Inc.
- Celtic Pharmaceutical Holdings L.P.
- EyeGene, Inc.
- DEKK-TEC, Inc.
- ISA Pharmaceuticals B.V.
- ImQuest Life Sciences
- TAU Therapeutics, LLC
- CytomX, LLC.

Customers who bought this item also bought

• Metastatic Colorectal Cancer - Pipeline Review, H2 2012
• Bladder Cancer - Pipeline Review, H2 2012
• Lymphoma - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Head And Neck Cancer - Pipeline Review, H2 2012
• Brain Cancer - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Cervical Cancer - Pipeline Review, H2 2012
• Osteoarthritis - Pipeline Review, H2 2012
• Prostate Cancer - Pipeline Review, H2 2012